title: Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
abstract: The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remission. The logistic regression analysis revealed that the strongest predictors of achieving clinical remission 1 year away from a first episode of non-affective psychosis were the length of duration of untreated psychosis (DUP), the severity of negative symptomatology and the educational level attained at baseline. The results suggest that: (1) patients with a lengthy DUP, a greater severity of negative symptomatology at baseline and with a lower education level are in a higher risk of not achieving a clinical remission during the first year of treatment; and (2) early intervention clinical programs should aim to reduce the length of DUP in order to provide a better outcome for patients.
authors.affiliation: University Hospital La Fe, Department of Psychiatry, Valencia, Spain.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Díaz
authors.forename: Jose María
authors.initials: JM
authors.lastname: Pelayo-Terán
authors.forename: Rocío
authors.initials: R
authors.lastname: Pérez-Iglesias
authors.forename: Ignacio
authors.initials: I
authors.lastname: Mata
authors.forename: Rafael
authors.initials: R
authors.lastname: Tabarés-Seisdedos
authors.forename: Paula
authors.initials: P
authors.lastname: Suárez-Pinilla
authors.forename: José Luis
authors.initials: JL
authors.lastname: Vázquez-Barquero
authors.forename: Benedicto
authors.initials: B
authors.lastname: Crespo-Facorro
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D004522:Educational Status; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D000077152:Olanzapine; D011379:Prognosis; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012074:Remission Induction; D012307:Risk Factors; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D061665:Time-to-Treatment; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine